Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Sander Kelderman, Bianca Heemskerk, Harm van Tinteren, Rob R. H. van den Brom, Geke A. P. Hospers, Alfonsus J. M. van den Eertwegh, Ellen W. Kapiteijn, Jan Willem B. de Groot, Patricia Soetekouw, Rob L. Jansen, Edward Fiets, Andrew J. S. Furness, Alexandra Renn, Marcin Krzystanek, Zoltan Szallasi, Paul Lorigan, Martin E. Gore, Ton N. M. Schumacher, John B. A. G. Haanen, James M. G. LarkinChristian U. Blank

Research output: Contribution to journalArticleAcademicpeer-review

74 Citations (Scopus)
Original languageEnglish
Pages (from-to)449-458
JournalCancer Immunology Immunotherapy
Volume63
Issue number5
DOIs
Publication statusPublished - May 2014

Keywords

  • Melanoma
  • Immunotherapy
  • Ipilimumab
  • Lactate dehydrogenase
  • Biomarker

Cite this

Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E. W., de Groot, J. W. B., Soetekouw, P., Jansen, R. L., Fiets, E., Furness, A. J. S., Renn, A., Krzystanek, M., Szallasi, Z., Lorigan, P., Gore, M. E., Schumacher, T. N. M., Haanen, J. B. A. G., ... Blank, C. U. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology Immunotherapy, 63(5), 449-458. https://doi.org/10.1007/s00262-014-1528-9